BBT002 for Chronic Obstructive Pulmonary Disease, Tested in Healthy Volunteers and Patients
Tests the safety of BBT002 in healthy volunteers and people with COPD.
Plain-language title generated from the registry record
Registry title: A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Key facts
- Where
- Chengdu, Guangzhou, Hangzhou, Hefei, Jiangmen, Nanchang, Qingyuan, Xinxiang, Xuzhou, and Yichang, ChinaSee the 11 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07288554, who can take part
Where in China
- Chengdu Fifth People's HospitalChengdu, ChinaTaking people
- The First Affiliated Hospital of Guangdong Medical UniversityGuangzhou, ChinaTaking people
- The third affiliated hosptial of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- The Second Hospital of Anhui Medical UnivesityHefei, ChinaTaking people
- Jiangmen Central HospitalJiangmen, ChinaTaking people
- Jiangxi Provincial People's HospitalNanchang, ChinaTaking people
- Qingyuan People's HospitalQingyuan, ChinaTaking people
- The First People's Hospital of Xinxiang CityXinxiang, ChinaTaking people
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaTaking people
- Yichang Central People's HospitalYichang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bambusa Therapeutics
- Trial code
- NCT07288554
- Record updated
- 22 July 2026
- Original description
This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Obstructive Pulmonary Disease (COPD).Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Obstructive Pulmonary Disease (COPD).
Inclusion: Age of 18-65 years (HVs), 35-75 years (patients); Body mass index between 18-32 kg/m², capped at 120 kg; Negative pregnancy tests for women of childbearing potential; Willingness to refrain from alcohol consumption for 24 hours prior to each study visit; Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers; Adequate contraception use (for men and women of childbearing potential); No clinically significant abnormalities or history of relevant diseases; Documented history of COPD with a post-bronchodilator FEV1/FVC < 0.70; FEV1 ≥ 30% and FEV1<80% predicted at screening.
Exclusion: Positive drug/alcohol tests or abnormal vital signs at screening or Day -1; Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV); Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections; History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders; History of drug/alcohol abuse in the past 2 years; History of severe allergic reactions or hypersensitivity; Current diagnosis of other significant pulmonary disease; Significant or unstable cardiovascular diseases; Recent clinically significant infection; Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function; Abnormal Electrocardiogram(ECG) findings; Inability to perform spirometry.